Modifying Immune Response & Outcomes in Amyotrophic Lateral Sclerosis (MIROCALS)

MIROCALS aims to find a new treatment for amyotrophic lateral sclerosis (ALS) by testing interleukin-2 (IL-2), a molecule that helps to regulate our immune system.

The aim is to develop a new therapy for ALS and through this novel trial design break the deadlock in drug development of other disease-modifying agents in ALS. It is hoped that this project will contribute to enhancing quality of life and care for people with ALS, and provide a robust model for Industry to encourage investment in ALS and other neurodegenerative diseases.


Pert Diagram

Project Partners

MIROCALS consortium involves 12 organisations in Europe conducting a phase II Proof of Concept / Proof of Mechanism Clinical Trial aiming to test the interleukin-2 (IL-2) as treatment for amyotrophic lateral sclerosis (ALS).

The science of the project is coordinated by Dr Gilbert Bensimon of the University Hospital of Nimes (France) which is the trial sponsor, and Professor P. Nigel Leigh of the Brighton and Sussex Medical School (UK).

Around them, the MIROCALS consortium brings together a strong partnership of: leading scientists and clinicians from six European laboratories in France, Italy, Sweden and UK; two clinical research organisations for professional biobanking and trial regulatory-compliant monitoring; the MND Association and an EU project management company.

University Hospital of Nimes
Nimes, France
Inserm Transfert
Icon plc
Généthon EN Q
1498139 Ny Logo En High
US Small Pos K
Tuoslogo Key
Queen Mary
Wgk Welcome Logo

This project is funded by the EU Horizon 2020 Programme, MND Association, Programme Hospitalier de Recherche Clinique, My Name’5 Doddie Foundation, Association Francaise contre les Myopathies, MND Scotland and Association pour la recherche sur la SLA.

For further information and support contact our MND Connect helpline

mndconnect 0808 802 6262